Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS
Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radio...
Main Authors: | Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst, Dirk Schadendorf |
---|---|
Format: | Article |
Language: | English |
Published: |
Medical Journals Sweden
2022-04-01
|
Series: | Acta Dermato-Venereologica |
Subjects: | |
Online Access: | https://medicaljournalssweden.se/actadv/article/view/293 |
Similar Items
-
Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
by: Jayson Miedema, MD, et al.
Published: (2018-01-01) -
Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma
by: Antonio J García Ruiz, et al.
Published: (2022-07-01) -
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
by: Glen J. Weiss, et al.
Published: (2011-12-01) -
Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
by: Maxwell G. Su, et al.
Published: (2020-09-01) -
Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma
by: Jaeyoung Yoon, MD, PhD
Published: (2021-01-01)